PATH vs RIGL
Uipath Inc (PATH) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the PATH and RIGL stock pages for the full models.
Not investment advice.